Kornimate/medical-research-clean huggingface dataset:
helicobacter pylori eradication after endoscopic resection of gastric tumors

Conditions: Gastric Tumor; Helicobacter Pylori; Endoscopic Resection; Metachronous Neoplasms

Summary: the purpose of this study is to determine whether helicobacter pylori eradication could reduce the new tumor development after endoscopic resection of gastric tumor.

the association between helicobacter pylori infection and development of gastric cancer has been established by epidemiologic studies. conversely, eradication of h. pylori showed no significant reduction of the incidence of gastric cancer in a large-scale, double-blind, randomized controlled trial. eradication of h. pylori to prevent cancer was only effective in the subgroup without precancerous lesions (i,e, dysplasia, intestinal metaplasia, and atrophy). in contrast, randomized prospective study in japan showed that h. pylori eradication after endoscopic resection of early gastric cancer significantly reduced metachronous gastric cancer. to solve this conflicting issue is critical because gastric cancer is the second leading cancer incidence worldwide, particularly korea, japan, and china have highest cancer incidence, and its incidence might decrease by h. pylori eradication treatment. with respect to therapeutic modality, endoscopic resection for early gastric cancer is currently the established treatment of choice in korea and japan because it has been proven to be both minimally invasive and effective in the curative treatment of early gastric cancer. endoscopic resection has also been performed in the gastric dysplasia because dysplasia has to some extent malignant potential although firm evidence is lacking. in comparison with surgical resection, endoscopic resection conserves remnant stomach. accordingly, patients treated with endoscopic resection have higher possibility for metachronous gastric cancer than those treated with surgical resection. so far, it has not yet been clearly established whether h pylori eradication for gastric tumors (early gastric cancer and gastric dysplasia) could reduce metachronous cancer. we performed randomized controlled, open-label trial on the effect of new cancer development after h pylori eradication for gastric tumors.

Eligibility criteria:
inclusion criteria: * h pylori infected patients with gastric low-grade dysplasia, high-grade dysplasia, and early gastric cancer * gastric tumor is completely removed through endoscopic resection. exclusion criteria: * patients underwent gastrectomy before enrollment * patients underwent endoscopic resection before enrollment * previous history of eradication for h. pylori * pregnancy * aged \ 75 yr old * patients underwent additional gastrectomy due to incomplete endoscopic resection

Keywords: gastric tumor helicobacter pylori endoscopic resection metachronous neoplasms
effectiveness of plaque score detection techniques

Conditions: Plaque, Dental

Summary: this study investigates the similarity between microbial plaque scores when assessing the entire dentition versus select teeth. the hypothesis posits that plaque buildup on single teeth mirrors that of the entire mouth, facilitating efficient plaque data collection and generalized deductions. additionally, the research explores the potential of dental monitoring© photos in accurately identifying plaque indexes, aiming to enhance plaque evaluation efficiency in dental appointments. the null hypothesis suggests no significant difference between full dentition plaque scores and selected teeth. results may streamline plaque tracking in patient appointments and enable remote monitoring, potentially detecting plaque accumulation issues earlier.

following the obtainment of participant consent, data will be collected during participant's routine prophylaxis appointment or during designated clinic time open for participants to volunteer. utilizing a scan box provided by dental monitoring©, a scan (series of intra-oral images) will be taken of the participant's dentition. the scan will be taken once before disclosing solution (erythrosine) is introduced to the dentition and once after. the disclosing solution will allow for visualization of plaque. the presence of plaque on all teeth surfaces will be recorded using the o'leary plaque index. no procedures (other than the intra-oral photos), interventions, evaluations or tests will be performed more frequently than they would be if the participant was not participating in the research. the only participant demographic information that will be recorded for this study is age. participants who opt to come in voluntarily for only data collection will not receive a prophylaxis. their plaque information will be collected, and they will be dismissed. oversight procedures in place: the scan boxes will be utilized by the investigators to take intra-oral photographs of each patient's dentition. these will be sterilized between each participant and stored in the college of dentistry's clinic lockers when not in use.

Eligibility criteria:
inclusion criteria: * 19-85 years old * patient at the university of nebraska medical center (unmc) college of dentistry * one molar, premolar or canine pe quadrant exclusion criteria: * no permanent dental devices (braces, splints) * less than 20 non-restored teeth present in the dentition
effect of smart phone application on the individualized management of chinese diabetic patients

Conditions: Diabetes Mellitus

Summary: the purpose of this study was to explore a model suitable for the individualized diabetic management based on the mobile application coaching and demonstrate its effect among the diabetic mellitus population.

the enrolled patients will be randomly divided into three groups: group of online self management, group of online mutual management and the control group. the estimated sample size was 78 patients for each group. all the patients attend two follow-up visits at the hospital, after 3 and 6 months. the data will be collected by a full-time recorder and analyzed using specific statistical software. the enumeration data are analyzed by chi-square test, while the measurement data are analyzed by one-way anova.

Eligibility criteria:
inclusion criteria: * physician diagnosis of dm for more than 6 months; * glycated hemoglobin more than or equal to 8% within 3 months; * age:18-65 years. exclusion criteria: * insulin pump users; * pregnant; * active substance, alcohol, or drug abuser; * psychotic or schizophrenic under active care; * severe hearing or visual impairment and other complications; * drug users (such as glucocorticoid or thyroid hormone) 3 months before the enrollment; * no smartphone access.

Keywords: smartphone app diabetic management lifestyle behaviors medication management
development of pharmacokinetics model in pregnancy women and fetus

Conditions: Preterm Labor; Preterm Premature Rupture of Membrane (PPROM)

Summary: pharmacokinetics analysis and development of pharmacokinetics model in pregnancy women and fetus


Eligibility criteria:
inclusion criteria: * 20 \<= age \< 50 * pregnant women who were administered intramuscular dexamethasone (ex) preterm labor) * pregnant women who were administered po clarithromycin (ex) pprom/intrauterine infection or inflammation) exclusion criteria: * who deny the study entrance * who administered study drug before transfer to tertiary hospital
training in subacromial impingement syndrome

Conditions: Subacromial Impingement Syndrome

Summary: a randomized controlled trial comparing a comprehensive supervised training regimen with a validated home-based regimen for subacromial impingement syndrome.

the purpose of the study is to compare a comprehensive supervised training regimen (str) based on latest evidence including heavy slow resistance training with a validated home-based regimen (htr). we hypothesized that the str would be superior to the htr. randomised control trial with blinded assessor. 126 consecutive patients with subacromial impingement syndrome were recruited and equally randomised to 12 weeks of either supervised training regimen (str), or home-based training regimen (htr). primary outcomes were constant score (cs) and shoulder rating questionnaire (srq) from baseline and 6 months after completed training. results were analyzed according to intention-to treat principles.

Eligibility criteria:
inclusion criteria: * subacromial impingement syndrome exclusion criteria: * ongoing claim with the labour market insurance, insurance company or comparable institution. * ongoing application for job revalidation or health related pension. * radiating neck pain. * ultrasound verified complete rotator cuff tendon lesion, as defined by hypoechoic or anechoic full thickness defect of the tendon, or absence of the tendon. * periarthritis humeroscapularis. * acute luxation or fracture of the shoulder. * ongoing steady analgetic treatment of other concomitant painful condition, unrelated to the patients shoulder problem.

Keywords: shoulder rotator cuff exercise
evaluation of acute post-thrombectomy complications for stroke

Conditions: Stroke, Complication; Stroke, Acute; Stroke Hemorrhagic

Summary: retrospective study to assess the incidence of acute complications after thrombectomy for stoke.

research in the computerized medical file of patients admitted to intensive care unit (icu) in the last 5 years for a stroke. searching for acute complications during the icu stay. looking for hemorrhagic, acute renal failure, hemodynamic support, neurologic degradation.

Eligibility criteria:
inclusion criteria: * \>18 year old * icu admitted patient for stroke and received thrombectomy exclusion criteria: * missing data
laluca research platform a prospective analysis of lung cancer diagnosis and management in clinical practice

Conditions: Lung Cancer

Summary: this is a prospective analysis of the diagnosis and treatment of lung cancer in a real-world setting. the aim of the project is to establish a clinical platform to collect representative data on molecular testing, sequence of systemic tumor therapy and other therapies, and disease progression of patients with lung cancer. a special focus will be on molecular biomarker testing and reflex ngs testing. another aim of the registry is the collection of quality indicators in lung cancer care. the results of the register will be used to describe the current state of care and to develop it further for the future.

the identification of driver-mutations, whose gene product can be specifically inhibited by targeted therapies, has markedly changed the diagnostic and therapeutic landscape for this tumor entity, leading to improved outcomes for patients with metastatic nsclc. the use of next generation sequencing (ngs) allows for detection of a multitude of different druggable mutations. in absence of a curative treatment approach and a druggable mutation the prognosis of lung cancer remains poor. thorough knowledge of the treatment reality, e.g. characteristics, diagnostic, treatment and outcome of unselected patients in real-iife practice, is crucial to evaluate and improve the quality of care for patients with lung cancer. the purpose of this project is to set up a clinical platform to document representative data on molecular testing, sequence of systemic treatment and other treatment modalities, and course of disease in patients with lung cancer. a particular focus is on molecular biomarker testing and ngs of patients before the start of first-line treatment. the data shall be used to assess the current state of care and to develop recommendations concerning topics that can be improved.

Eligibility criteria:
inclusion criteria: * informed consent * histologically confirmed lung cancer * age ≥ 18 years * able to understand and willing to sign written informed consent and to complete patient-reported-outcome assessment instruments exclusion criteria: -

Keywords: ngs testing
a safety study of ttp4000 in subjects with alzheimer's disease

Conditions: Alzheimer's Disease

Summary: the purpose of the study is to examine the safety, tolerability, immunogenicity and pharmacokinetics of ttp4000 in subjects with alzheimer's disease with mild cognitive impairment.


Eligibility criteria:
inclusion criteria: * males or females ≥ 50 years of age. * body mass index (bmi) of 18 to 35 kg/m2, inclusive. * weight ≥ 50 kg. * alzheimer's disease according to the dsm-iv-tr criteria and a score between 20 and 26 on the mini mental state exam. * subject must have a medical history for at least 6 months prior to screening (confirmed by medical records) of a diagnosis of mild alzheimer's disease. exclusion criteria: * current evidence or history within the last 3 years of a neurological or psychiatric illness that could contribute to dementia, including, but not limited to: epilepsy, focal brain lesion, parkinson's disease, seizure disorder, or head injury with loss of consciousness; dsm-iv-tr criteria for any major psychiatric disorder, including psychosis, major depression, and bipolar disorder. * participation and dosing in another clinical trial, involving any marketed or investigational drug, within 30 days before screening visit.
specific bile microorganisms caused intra-abdominal abscess on pancreaticoduodenectomy patients: customized antibiotics and antifungal medication may be necessary

Conditions: Intraabdominal Abscess After Procedure

Summary: background intra-abdominal abscess (iaa) is one of the most serious surgical infectious complications on pancreaticoduodenectomy (pd) patients. preoperative biliary drainage (pbd) is considered as a risk of surgical infectious complications. however, the reason why pbd caused iaa was unknown. in this study, we hypothesize that bile contamination may increase the rate of iaa as bile from residual common bile duct (cbd) leaks and contaminates the abdominal cavity. methods we retrospectively collected pd patients with performance of bile culture between 2007 and 2019 in our institute. as to bile culture, we used a swab to do intraoperative bile cultures after transection of the cbd. iaa was defined as a postoperative fluid collection managed by ct-guided placement of drains with documental bacteriological culture.


Eligibility criteria:
inclusion criteria: * all pancreaticoduodenectomy patients exclusion criteria: * no bile cultures

Keywords: pancreaticoduodenectomy, biliary drainage, positive bile culture, intra-abdominal abscess, surgical complication
immediate effects of manipulation versus stretching on upper trapezius pressure pain thresholds

Conditions: Neurophysiological Mechanisms Manipulation

Summary: the purpose of this study is to determine the immediate effects of cervicothoracic manipulation and upper trapezius stretching on upper trapezius pressure pain threshold and cervical rom.


Eligibility criteria:
inclusion criteria: 1. absence of current neck pain 2. aged 18 - 70 years 3. able to lie on stomach or back without difficulty exclusion criteria: 1. 'red flag' items indicated in neck medical screening questionnaire such as history of a tumor, bone fracture, metabolic diseases, rheumatoid arthritis, osteoporosis, severe atherosclerosis, prolonged history of steroid use, etc. 2. history of neck whiplash injury 3. diagnosis from physician of cervical spinal stenosis (narrowing of spinal canal) or presence of symptoms (pain, pins and needles, numbness) down both arms 4. presence of central nervous system involvement such as exaggerated reflexes, changes in sensation in the hands, muscle wasting in the hands, impaired sensation of the face, altered taste, and presence of abnormal reflexes 5. evidence of neurological signs consistent with nerve root entrapment (pinched nerve in the neck) 6. prior surgery to neck or upper back 7. a medical condition which may influence assessment of pain or pressure pain thresholds (i.e. taking analgesics, sedatives, history of substance abuse, or cognitive deficiency) 8. diagnosis from physician of fibromyalgia syndrome 9. currently pregnant, or could be pregnant
assessing an oral janus kinase inhibitor, azd4205, in combination with osimertinib in patients who have advanced non-small cell lung cancer

Conditions: Nonsmall Cell Lung Cancer

Summary: this study will treat patients with advanced nsclc who have progressed following prior therapy. this is the first time this drug has ever been tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. it will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy and in combination with osimertinib.

a phase i/ii, open-label, multicentre study to investigate the safety, tolerability, pharmacokinetics and anti-tumour activity of azd4205 as monotherapy or in combination with osimertinib in patients with egfr mutant advanced stage non-small cell lung cancer (nsclc). this study includes dose escalation part and dose expansion part.

Eligibility criteria:
inclusion criteria: 1. obtained written informed consent 2. patients must have histological or cytological confirmation of activating egfr mutation positive nsclc and have failed prior egfr tkis treatment. 3. patients must exhibit eastern cooperative oncology group (ecog) performance status 0-1 4. adequate bone marrow reserve and organ system functions exclusion criteria: 1. any unsolved toxicity \> ctcae grade 1 from previous anti-cancer therapy (except alopecia) 2. active viral or bacterial infections; 3. active or latent tuberculosis; 4. history of interstitial lung disease (ild) 5. history of heart failure or qt interval prolongation 6. immunodeficiency diseases; 7. active cns metastases 8. treatment with an egfr tki (e.g., erlotinib or gefitinib) within 8 days or approximately 5 x half-life, whichever is longer, of the first dose of study treatment
a study to evaluate the efficacy and safety of dbpr108 100 mg in type 2 diabetes mellitus patients

Conditions: Type 2 Diabetes Mellitus

Summary: this study will evaluate the efficacy and safety of 100 mg drbp108 tablets in the treatment of type 2 diabetes mellitus. a total of 750 subjects will be randomly allocated to three groups: drbp108, active comparator and placebo comparator, in a 3:1:1 ratio. the purpose of this study is to evaluate whether 24 weeks of drbp108 treatment will adequately reduce hemoglobin a1c levels in t2dm subjects.


Eligibility criteria:
inclusion criteria: * subjects who meet the world health organization(who) (1999) criteria for the diagnosis and classification criteria for type 2 diabetes; * 18 ≤ age ≤ 75 years old, male or female; * 19kg/m\^2 ≤ body mass index（bmi ）≤ 35kg/m\^2; * subjects with type 2 diabetes mellitus who did not regularly take oral hypoglycemic drugs at least 8 weeks before screening (i.e., continuous medication for \<1 week); * 7.0% ≤ hba1c ≤ 9.5%; * subjects voluntarily participate in the trial and sign the informed consent form; * subjects agree to use contraception from the signing of the informed consent form to the end of 1 month of the last medication. exclusion criteria: * fpg \> 13.9 mmol/l; * a history of severe hypoglycemia (that is, hypoglycemia with severe cognitive impairment and requiring other measures to help recover); * a history of allergy to similar drugs (dpp-4 inhibitors) or those who have been judged by the investigator to be allergic to tested drugs; * uncured hyperthyroidism or other diseases may cause secondary blood sugar elevation; * continuous use of glucocorticoids within 4 weeks prior to screening or may uninterrupted use glucocorticoids ≥14 days during the trial (except for external use and inhalation) * subjects with chronic bowel disease associated with inflammatory bowel disease, partial intestinal obstruction, or obvious digestive and absorption disorders; * subjects with infectious diseases(all positive for hbsag, hbeag, hbcab, or positive for hepatitis c antibody, or positive for anti-hiv antibody); female subjects of childbearing age are positive in pregnancy test or are lactating; * subjects with a history of alcoholism or drug abuse; * subjects have the clinically significant unstable diseases; * not suitable for this clinical trial judged by the investigator.

Keywords: dbpr108 type 2 diabetes mellitus dpp4 inhibitor
evaluation of two new innovative haemostasis tests: measurement of the active form of gtp-bound rap1b (arap1b) in platelets and the pro and antithrombotic balance of circulating endothelial microvesicles (patemv) (innov-ckd test)

Conditions: Chronic Renal Failure

Summary: the aim of this project is to develop two biomarkers to assess the thrombotic and hemorrhagic risk of patients with chronic renal failure (ckd) treated with antiplatelet drugs following the occurrence of an acute coronary syndrome (acs). these biomarkers will help to adapt antiplatelet therapy on an individual basis (intensity, duration of antiplatelet treatment) and thus reduce the risk of thrombotic and hemorrhagic events in this particularly fragile population. the methods for measuring these two highly innovative biomarkers are currently being developed. the first biomarker corresponds to the measurement of an intraplatelet molecule, rap1b in its active form (arap1b). the second biomarker is the measurement of the pro-antithrombotic balance of circulating endothelial microvesicles (patemv), a reflection of endothelial dysfunction. an automated method for biomarker measurement will be developed in partnership with the industrial partners stago and biocytex during the project.


Eligibility criteria:
inclusion criteria: * healthy subjects (group 1): dfg\>70 ml/mn/1.73m2 in ckd-epi, age 18-85 years old, consent required, affiliated to social security. * antiplatelet agents-naïve ckd patients (group 2): dfg\<30 ml/mn/1.73m2 in ckd-epi, age 18-85 years old, consent required, affiliated to social security. * ckd patients receiving antiplatelet agents (group 3): dfg\<30 ml/mn/1.73m2 in ckd-epi, receiving antiplatelet agents, age 18-85 years old, consent required, affiliated with social security. * patients with constitutional platelet dysfunction (group 4): dfg\>70 ml/min/1.73m2 in ckd-epi, age 18-85 years old, consent required, social security affiliated, constitutional haemorrhagic syndrome * coronary patients (group 5): dfg\>70 ml/mn/1.73m2 in ckd-epi, age 18-85 years old, consent required, social security affiliated, acute coronary syndrome in the previous month requiring aap. exclusion criteria: * for all the groups : subjects refusing to participate in the study, pregnant or breastfeeding women, minors (except for special consent), adults subject to a legal protection measure or unable to express their consent (persons under guardianship or curatorship), persons deprived of their rights of liberty by judicial or administrative decision (persons in a situation of social fragility), persons at the end of life.